Biomerica, Inc. cash flow to debt ratio of -838.65% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Biomerica, Inc.'s free cash flow has increased -29.18% from $-5.48M last year to $-3.88M, signaling increasing performance

Biomerica, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Biomerica, Inc.'s debt has decreased relative to shareholder equity from 0.12 last year to 0.06 today, signaling strengthened financials

Biomerica, Inc. has a net cash position, so leverage is healthy.

Biomerica, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Biomerica, Inc.'s profit margin has increased (-12.60%) in the last year from -110.40% to -96.49%, signaling increasing performance

Biomerica, Inc.'s short-term assets of $4.88M exceed its short-term liabilities of $1.74M

Biomerica, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Biomerica, Inc.'s return on equity of -98.14%, is lower than 15.00%, indicating bad performance

Biomerica, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Biomerica, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Biomerica, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Biomerica, Inc. has negative free cash flow, indicating cash burn

Biomerica, Inc.'s yearly earnings has increased -16.81% since last year from $-5.98M to $-4.97M, signaling increasing performance

Biomerica, Inc.'s yearly revenue has decreased 1.92% since last year from $5.42M to $5.31M, signaling decreasing performance

ROIC -152.51% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Biomerica, Inc.'s 3-year revenue CAGR of -34.47% is negative, indicating declining revenue over the past 3 years

Biomerica, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Biomerica, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Biomerica, Inc. has insufficient data to evaluate this check.

Biomerica, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biomerica, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Biomerica, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Biomerica, Inc. is overvalued relative to its fair value price of -16.17 based on Earnings Fair Value model

Biomerica, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Biomerica, Inc. has a price-to-book ratio of 1.48x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Biomerica, Inc. has a price-to-sales ratio of 1.13x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue